Zynex (ZYXI) Downgraded to “Sell” at ValuEngine

ValuEngine downgraded shares of Zynex (OTCMKTS:ZYXI) from a hold rating to a sell rating in a research report report published on Wednesday.

Several other brokerages have also recently commented on ZYXI. B. Riley assumed coverage on shares of Zynex in a report on Wednesday, October 10th. They set a buy rating and a $7.00 target price for the company. Zacks Investment Research cut shares of Zynex from a buy rating to a hold rating and set a $3.50 target price for the company. in a report on Saturday, November 17th.

Shares of ZYXI opened at $3.10 on Wednesday. Zynex has a 12 month low of $2.40 and a 12 month high of $5.50. The firm has a market cap of $94.87 million, a P/E ratio of 14.09 and a beta of 0.80.

Zynex (OTCMKTS:ZYXI) last announced its earnings results on Tuesday, November 6th. The company reported $0.08 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.01. Zynex had a net margin of 33.33% and a return on equity of 152.81%. The business had revenue of $8.13 million during the quarter, compared to analysts’ expectations of $7.96 million. Analysts forecast that Zynex will post 0.28 EPS for the current fiscal year.

Zynex Company Profile

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

See Also: Moving Average – How it Helps Investors in Stock Selection

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply